放射治疗改善了在免疫疗法后的寡进后NSCLC的存活率:一个队列研究
Lauren Julia Brown1,2,3,4, Julie Ahn1,2, Bo Gao1,2,3
1Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia.
JTO clinical and research reports
|October 21, 2024
概括
放射治疗改善了转移性非小细胞肺癌 (NSCLC) 患者的存活率,这些患者在免疫检查点抑制剂 (ICI) 后经历了寡进. 大脑转移增加了寡头进展的可能性,而肝转移降低了它.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床试验 临床试验
背景情况:
- 对于转移性非小细胞肺癌 (NSCLC) 的第一线免疫检查点抑制剂 (ICI) 后的寡头进展模式需要进一步定义.
- 新出现的数据表明,向放射治疗可以提高ICI治疗后进展的患者的生存结果.
研究的目的:
- 在一线ICI治疗后,在转移性NSCLC患者中描述寡头进展的频率和解剖分布.
- 评估放射治疗对这一患者队伍的整体生存期 (OS) 和无进展生存期-2 (PFS2) 的影响.
主要方法:
- 追溯队列研究涉及159名转移性NSCLC患者,接受一线ICI治疗.
- 对寡头进展模式的分析,包括与基线转移 (大脑,肝脏) 的关联.
- 接受放射治疗的寡进症患者与没有接受放射治疗的患者之间的生存结果 (PFS2,OS) 的比较.
主要成果:
- 在第一个进展时,在39.0%的患者中发生了寡度进展.
- 大脑转移与较高的寡头进展概率相关 (OR=2.44,p=0.04),主要是内转移.
- 肝转移与较低的寡头进展可能性相关 (OR=0.17,p<0.01).
- 与没有接受放射治疗的患者相比,接受放射治疗的寡进症患者表现出改善的PFS2 (17 vs 11.5个月) 和OS (23 vs 13个月).
- 在放射治疗和非放射治疗组之间没有观察到PFS2或OS系统性进展的显著差异.
结论:
- 放射疗法显著改善了转移性NSCLC患者的OS和PFS2,在一线ICI后出现寡进.
- 患有基线大脑转移的患者患有寡头进展的可能性增加.
- 进一步的前性研究对于优化这种患者群体的管理策略至关重要.
相关概念视频
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K